FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313339834> ?p ?o ?g. }

• W4313339834 endingPage "640" @default.
• W4313339834 startingPage "629" @default.
• W4313339834 abstract "Guselkumab, an anti-interleukin-23 biologic therapy, has been shown to significantly reduce disease activity and improve patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis in clinical trials. However, characterization of the real-world effectiveness of guselkumab among patients living in the USA and Canada is warranted.Patients who participated in the CorEvitas Psoriasis Registry between 18 July 2017 and 10 March 2020 were included if they met the following criteria: Investigator's Global Assessment (IGA) score ≥ 3 and body surface area (BSA) ≥ 10% (moderate-to-severe psoriasis), initiated guselkumab at a registry (index) visit, and had a registry follow-up visit after 9-12 months of persistent guselkumab therapy. Data were retrieved for baseline patient demographics and disease characteristics, treatment history, disease activity, and PROMs. Outcomes were assessed at index and follow-up visits; response rates and mean changes were calculated.Among 113 patients, mean age was 49.7 years, mean psoriasis duration was 17.5 years, and 65.5% of patients were biologic experienced. At baseline, mean IGA score was 3.3, Psoriasis Area Severity Index (PASI) score was 13.6, and Dermatology Life Quality Index (DLQI) score was 9.6. At follow-up, IGA 0/1, PASI 90, and DLQI 0/1 were achieved by 62.2%, 56.8%, and 54.7% of patients, respectively. Statistically significant improvements were observed in all disease activity scores and PROMs, including the EuroQoL Visual Analogue Scale, Work Productivity and Activity Impairment, Patient Global Assessment, fatigue, skin pain, and itch (p < 0.05).This real-world study showed that patients with moderate-to-severe psoriasis who received 9-12 months of persistent guselkumab therapy experienced improvements in disease severity and PROMs." @default.
• W4313339834 created "2023-01-06" @default.
• W4313339834 creator A5005342849 @default.
• W4313339834 creator A5014696794 @default.
• W4313339834 creator A5024388213 @default.
• W4313339834 creator A5033613047 @default.
• W4313339834 creator A5033903141 @default.
• W4313339834 creator A5040462381 @default.
• W4313339834 creator A5043153151 @default.
• W4313339834 creator A5060732331 @default.
• W4313339834 creator A5071345428 @default.
• W4313339834 creator A5089128754 @default.
• W4313339834 date "2022-12-31" @default.
• W4313339834 modified "2023-10-11" @default.
• W4313339834 title "Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry" @default.
• W4313339834 cites W1971301895 @default.
• W4313339834 cites W2017932566 @default.
• W4313339834 cites W2036973079 @default.
• W4313339834 cites W2086325363 @default.
• W4313339834 cites W2096991001 @default.
• W4313339834 cites W2473786944 @default.
• W4313339834 cites W2570140560 @default.
• W4313339834 cites W2570141807 @default.
• W4313339834 cites W2751316297 @default.
• W4313339834 cites W2765883502 @default.
• W4313339834 cites W2898518424 @default.
• W4313339834 cites W2912058252 @default.
• W4313339834 cites W2938286893 @default.
• W4313339834 cites W3013434472 @default.
• W4313339834 cites W3016621057 @default.
• W4313339834 cites W3033338019 @default.
• W4313339834 cites W3035593501 @default.
• W4313339834 cites W3040238256 @default.
• W4313339834 cites W3041168317 @default.
• W4313339834 cites W3107651834 @default.
• W4313339834 cites W3115852192 @default.
• W4313339834 cites W3179294156 @default.
• W4313339834 cites W3200575265 @default.
• W4313339834 cites W3203792231 @default.
• W4313339834 cites W3205535255 @default.
• W4313339834 cites W3214873397 @default.
• W4313339834 cites W3215546592 @default.
• W4313339834 cites W4310942033 @default.
• W4313339834 doi "https://doi.org/10.1007/s13555-022-00879-8" @default.
• W4313339834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585606" @default.
• W4313339834 hasPublicationYear "2022" @default.
• W4313339834 type Work @default.
• W4313339834 citedByCount "1" @default.
• W4313339834 countsByYear W43133398342023 @default.
• W4313339834 crossrefType "journal-article" @default.
• W4313339834 hasAuthorship W4313339834A5005342849 @default.
• W4313339834 hasAuthorship W4313339834A5014696794 @default.
• W4313339834 hasAuthorship W4313339834A5024388213 @default.
• W4313339834 hasAuthorship W4313339834A5033613047 @default.
• W4313339834 hasAuthorship W4313339834A5033903141 @default.
• W4313339834 hasAuthorship W4313339834A5040462381 @default.
• W4313339834 hasAuthorship W4313339834A5043153151 @default.
• W4313339834 hasAuthorship W4313339834A5060732331 @default.
• W4313339834 hasAuthorship W4313339834A5071345428 @default.
• W4313339834 hasAuthorship W4313339834A5089128754 @default.
• W4313339834 hasBestOaLocation W43133398341 @default.
• W4313339834 hasConcept C126322002 @default.
• W4313339834 hasConcept C14184104 @default.
• W4313339834 hasConcept C159110408 @default.
• W4313339834 hasConcept C16005928 @default.
• W4313339834 hasConcept C1862650 @default.
• W4313339834 hasConcept C2776173921 @default.
• W4313339834 hasConcept C2777011040 @default.
• W4313339834 hasConcept C2777501473 @default.
• W4313339834 hasConcept C2779951463 @default.
• W4313339834 hasConcept C2780564577 @default.
• W4313339834 hasConcept C30036603 @default.
• W4313339834 hasConcept C71924100 @default.
• W4313339834 hasConceptScore W4313339834C126322002 @default.
• W4313339834 hasConceptScore W4313339834C14184104 @default.
• W4313339834 hasConceptScore W4313339834C159110408 @default.
• W4313339834 hasConceptScore W4313339834C16005928 @default.
• W4313339834 hasConceptScore W4313339834C1862650 @default.
• W4313339834 hasConceptScore W4313339834C2776173921 @default.
• W4313339834 hasConceptScore W4313339834C2777011040 @default.
• W4313339834 hasConceptScore W4313339834C2777501473 @default.
• W4313339834 hasConceptScore W4313339834C2779951463 @default.
• W4313339834 hasConceptScore W4313339834C2780564577 @default.
• W4313339834 hasConceptScore W4313339834C30036603 @default.
• W4313339834 hasConceptScore W4313339834C71924100 @default.
• W4313339834 hasFunder F4320337449 @default.
• W4313339834 hasIssue "2" @default.
• W4313339834 hasLocation W43133398341 @default.
• W4313339834 hasLocation W43133398342 @default.
• W4313339834 hasLocation W43133398343 @default.
• W4313339834 hasOpenAccess W4313339834 @default.
• W4313339834 hasPrimaryLocation W43133398341 @default.
• W4313339834 hasRelatedWork W1752862699 @default.
• W4313339834 hasRelatedWork W2461170543 @default.
• W4313339834 hasRelatedWork W2462324581 @default.
• W4313339834 hasRelatedWork W2766413417 @default.
• W4313339834 hasRelatedWork W2998923669 @default.
• W4313339834 hasRelatedWork W3091437709 @default.

• next